MD Research
Long/short equity, integrated investing, 360 Biotech, insightful news

A Medical Doctor's Perspective On MannKind Corp.'s Revolutionary Diabetes Mellitus Treatments


MannKind Corporation (NASDAQ:MNKD), a small cap biotechnology in Valencia, California, planted the catalytic seeds for revolutionary diabetes treatment more than a decade ago that are now materializing for aggressive growth. In this research report, the author will provide a comprehensive analysis of MNKD through his unique views as a practicing MD, researcher, and investor.

(click to enlarge)

Revolution in Diabetes Mellitus Treatments

The market for diabetes mellitus is increasingly gigantic. Research estimates that over 25 million or 8.3% of the U.S. population have diabetes mellitus in 2011. There are 1.9 million new cases each year. Overweight and obesity are quite common in the U.S. as well as modernizing nations. Being overweight leads to obesity; Obesity leads to...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details